Immunonutritional contribution of gut microbiota to fatty liver disease.

Immunonutritional contribution of gut microbiota to fatty liver disease. Nutr Hosp. 2019 Dec 03;: Authors: Fernández-Musoles R, García Tejedor A, Laparra JM Abstract Non-alcoholic fatty liver disease (NAFLD) is indisputably the most widespread liver disease worldwide, leading to a significant increase in patient morbidity, mortality, and health care utilization. The gut microbiota and its genome (microbiome) have emerged as a novel modulator of the immunometabolic processes that NAFLD implies, but microbiota-targeted interventions have resulted both astounding and at the same time unsuccessful. The most relevant alteration appears to be the overgrowth of Gram-negative bacteria, characterized by an increased ratio of Firmicutes to Bacteroidetes, although current evidence indicates species- and strain-specific effects influencing energy harvest, the host's innate and adaptive immune systems, and epigenetic regulation as determinants of the immunomodulatory milieu in NAFLD. The genera Lactobacillus and Bifidobacterium deserve special attention since many of their probiotic strains are marketed for human consumption, even more so when considering that, in conjunction with prebiotics, they are potential modulators of gut microbiota composition and/or metabolic activity. Here, a better understanding of the major intestinal microbial factors with a detrimental or preventive role in NAFLD, and of the dynamic interplay between gut microbiome and hos...
Source: Nutricion Hospitalaria - Category: Nutrition Authors: Tags: Nutr Hosp Source Type: research

Related Links:

Non-alcoholic fatty liver disease (NAFLD) figures prominently into the clinical hepatology landscape. NAFLD represents a disease spectrum comprising simple steatosis, steatosis with elevated liver enzymes, and non-alcoholic steatohepatitis (NASH), the entity with clear potential for fibrosis progression. Risk factors associated with fibrosis progression in NASH include histologic findings of lobular inflammation and any fibrosis as well as clinical comorbidities that include type 2 diabetes, obesity, and metabolic syndrome. Liver biopsy remains the gold standard in evaluating NASH; however, noninvasive methods are accumula...
Source: Gastroenterology Clinics of North America - Category: Gastroenterology Authors: Source Type: research
AbstractNon ‐alcoholic fatty liver disease (NAFLD) is one of the most common liver disorders worldwide. NAFLD is considered to be the hepatic component of metabolic syndrome because its features are very similar to those of metabolic disorders such as obesity, inflammation, insulin resistance, and type 2 diab etes. It is clear that NAFLD and type 2 diabetes have a close relationship. However, the exact mechanisms underlying the pathogenesis and progression of NAFLD are still incompletely understood1 ‐3).
Source: Journal of Diabetes Investigation - Category: Endocrinology Authors: Tags: Commentary Source Type: research
CONCLUSION: A significant percentage of the American general population is afflicted by BAFLD and these patients tend to have more advanced liver fibrosis. PMID: 31749901 [PubMed]
Source: World Journal of Hepatology - Category: Gastroenterology Tags: World J Hepatol Source Type: research
In conclusion, the information displayed in this review support that the ghrelin system could be an appealing strategy for the treatment of liver disease.
Source: Reviews in Endocrine and Metabolic Disorders - Category: Endocrinology Source Type: research
In conclusion, the information displayed in this review support that the ghrelin system could be an appealing strategy for the treatment of liver disease. PMID: 31758299 [PubMed - as supplied by publisher]
Source: ENDOCR REV - Category: Endocrinology Authors: Tags: Rev Endocr Metab Disord Source Type: research
Publication date: Available online 17 October 2019Source: Trends in Endocrinology &MetabolismAuthor(s): Daniela Stols-Gonçalves, G. Kees Hovingh, Max Nieuwdorp, Adriaan G. HolleboomThe prevalence of non-alcoholic fatty liver disease (NAFLD) is strongly increasing and may put patients at increased risk for atherosclerotic cardiovascular disease (asCVD). Both disease phenotypes often co-occur, in the case of obesity, insulin resistance, diabetes mellitus type 2, and the metabolic syndrome. We explore the pathogenesis of NAFLD, the epidemiology of asCVD in NAFLD patients, shared drivers of both phenotypes, and fact...
Source: Trends in Endocrinology and Metabolism - Category: Endocrinology Source Type: research
CONCLUSION: Despite some limitations of our study, such as the small number of patients, and the use of two different methods of evaluation (biopsy and elastography), the data obtained allow us to conclude that of the 39 evaluated cases, 33% (13) presented progression of fibrosis and the total group of 50 patients, 42% had cirrhosis or died due to liver disease. The presence of NASH on hepatic biopsy did not prove to be, in our study, a predictive of the evolution of hepatic fibrosis in the patients.RESUMO CONTEXTO: A doen ça hepática gordurosa não alcoólica vem sendo diagnosticada com frequ&eci...
Source: Arquivos de Gastroenterologia - Category: Gastroenterology Source Type: research
Non-alcoholic fatty liver disease (NAFLD) is a growing challenge to global public health. It is defined as the increased accumulation of hepatic triglyceride (>5%) in the absence of excessive alcohol consumption or other causes of liver disease. The NAFLD spectrum encompasses steatosis (non-alcoholic fatty liver, NAFL) and non-alcoholic steatohepatitis (NASH), an inflammatory form of the condition marked by the presence of hepatocyte damage and progressive fibrosis that may lead to cirrhosis.[1,2] Although NAFLD may occur in patients with normal weight, it is closely associated with the presence of the metabolic syndrom...
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research
na Loguercio Alessandro Federico Non-alcoholic fatty liver disease (NAFLD) is considered a predominant chronic liver disease worldwide and a component of metabolic syndrome. Due to its relationship with multiple organs, it is extremely complex to precisely define its pathogenesis as well as to set appropriate therapeutic and preventive strategies. Endocrine disruptors (EDCs) in general, and bisphenol A (BPA) in particular, are a heterogeneous group of substances, largely distributed in daily use items, able to interfere with the normal signaling of several hormones that seem to be related to type 2 diabetes mellitus ...
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Review Source Type: research
The objective of the present study was to investigate the association between hair and urine Al levels and obesity.MethodsA total of 206 lean and 205 obese non-occupationally exposed subjects (30-50 y.o.) were enrolled in the study. Hair and urine Al levels were assessed with ICP-MS. Laboratory quality control was performed using the certified reference materials of human hair, plasma, and urine.ResultsHair and urinary Al levels in obese subjects were significantly higher by 31% and 46% compared to the control levels, respectively. The presence of hypertension (41% cases), atherosclerosis (8%), type 2 diabetes melli...
Source: Journal of Trace Elements in Medicine and Biology - Category: Biochemistry Source Type: research
More News: Alcoholism | Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Fatty Liver Disease (FLD) | Health Management | Liver | Liver Disease | Metabolic Syndrome | Non-alcoholic Fatty Liver Diseases (NAFLD) | Nutrition | Obesity | Probiotics | Urology & Nephrology